IONIS PHARMACEUTICALS INC 8-K

What Happened

• Ionis Pharmaceuticals (IONS) filed an 8-K reporting the appointment of Ludwig N. Hantson to its Board of Directors effective June 4, 2026 (immediately after the 2026 Annual Meeting). Dr. Hantson has more than 30 years of biopharma leadership, including CEO of Alexion (2017–2021), president of Baxter Bioscience (led Baxalta spin-off), senior roles at Novartis, and earlier roles at Johnson & Johnson. He will receive the company’s standard non‑employee director cash and equity compensation and will enter into the company’s standard indemnity agreement. The company also noted that Peter N. Reikes was previously appointed effective June 4, 2026 (announced March 9, 2026).
• The company held its virtual Annual Meeting on June 4, 2026 and reported vote results for five proposals, each approved by shareholders. A press release announcing Dr. Hantson’s appointment was furnished as Exhibit 99.1 on June 8, 2026.

Key Details

• Director appointment effective: June 4, 2026; appointee: Ludwig N. Hantson (Ph.D., University of Louvain).
• Election votes (selected): Spencer R. Berthelsen — For 119,824,353 / Against 20,816,547 / Absent 98,115; Joan E. Herman — For 135,599,646 / Against 5,076,895 / Absent 62,474. Broker non-votes: 12,305,695 for director elections.
• Say-on-pay (advisory) approved: For 135,537,973 / Against 5,088,105 / Abstain 112,937 / Broker non-votes 12,305,695.
• Equity plan approvals: 2011 Equity Incentive Plan increased by 9,500,000 shares to 52,000,000 — approved For 108,377,084 / Against 32,303,288; 2000 ESPP increased by 750,000 shares and removed termination date — approved For 140,348,001 / Against 332,204.
• Audit ratification: Ernst & Young LLP ratified as independent auditors for 2026 — For 148,893,646 / Against 4,000,539.

Why It Matters

• Governance: Adding Ludwig Hantson brings a seasoned commercial and executive leader to Ionis’ board, potentially strengthening oversight and strategic experience at the board level. His appointment and standard director compensation are disclosed and there are no special arrangements.
• Shareholder approvals: Investors approved executive compensation (say-on-pay) and two equity-plan amendments. The 2011 Equity Incentive Plan increase (9.5M additional shares) and ESPP changes expand the pool of shares available for grants and purchases, which can enable talent retention but may lead to future dilution when shares are issued.
• Audit continuity: Ratification of Ernst & Young as auditor confirms continuity of independent audit oversight for 2026.

Exhibits: Press release dated June 8, 2026 (Exhibit 99.1) was furnished with the filing.